Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR plus advanced triple-negative breast cancer (aTNBC) - Cortes, J; Crown, J; Awada, A (Eur J Cancer, 2015)